glp-1 news today 2025 october 9 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with GLP-1 Weight-Loss Drug Demonstration Begins
Pay in 4 interest-free payments of $7.48 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13























